Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.31
CLVS's Cash to Debt is ranked lower than
76% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. CLVS: 1.31 )
Ranked among companies with meaningful Cash to Debt only.
CLVS' s 10-Year Cash to Debt Range
Min: 0.91  Med: 10000.00 Max: No Debt
Current: 1.31
F-Score: 1
Z-Score: 1.88
M-Score: -8.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1163.00
CLVS's Operating margin (%) is ranked lower than
80% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. CLVS: -1163.00 )
Ranked among companies with meaningful Operating margin (%) only.
CLVS' s 10-Year Operating margin (%) Range
Min: -1163  Med: -1163.00 Max: -1163
Current: -1163
Net-margin (%) -1174.54
CLVS's Net-margin (%) is ranked lower than
80% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. CLVS: -1174.54 )
Ranked among companies with meaningful Net-margin (%) only.
CLVS' s 10-Year Net-margin (%) Range
Min: -1174.54  Med: -1174.54 Max: -1174.54
Current: -1174.54
ROE (%) -71.02
CLVS's ROE (%) is ranked lower than
71% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CLVS: -71.02 )
Ranked among companies with meaningful ROE (%) only.
CLVS' s 10-Year ROE (%) Range
Min: -144.26  Med: -47.18 Max: -26.78
Current: -71.02
-144.26
-26.78
ROA (%) -31.98
CLVS's ROA (%) is ranked lower than
54% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. CLVS: -31.98 )
Ranked among companies with meaningful ROA (%) only.
CLVS' s 10-Year ROA (%) Range
Min: -65.51  Med: -36.71 Max: -21.25
Current: -31.98
-65.51
-21.25
ROC (Joel Greenblatt) (%) -8217.49
CLVS's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. CLVS: -8217.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8446.45  Med: -7022.22 Max: -4951.81
Current: -8217.49
-8446.45
-4951.81
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CLVS Guru Trades in Q3 2014

Jim Simons 22,000 sh (New)
» More
Q4 2014

CLVS Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

CLVS Guru Trades in Q1 2015

Steven Cohen 100,000 sh (unchged)
» More
Q2 2015

CLVS Guru Trades in Q2 2015

Steven Cohen 117,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.77
CLVS's P/B is ranked lower than
84% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CLVS: 13.77 )
Ranked among companies with meaningful P/B only.
CLVS' s 10-Year P/B Range
Min: 2.83  Med: 5.73 Max: 13.77
Current: 13.77
2.83
13.77
Current Ratio 6.22
CLVS's Current Ratio is ranked higher than
61% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CLVS: 6.22 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s 10-Year Current Ratio Range
Min: 0.86  Med: 11.91 Max: 31.09
Current: 6.22
0.86
31.09
Quick Ratio 6.22
CLVS's Quick Ratio is ranked higher than
62% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. CLVS: 6.22 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s 10-Year Quick Ratio Range
Min: 0.86  Med: 11.91 Max: 31.09
Current: 6.22
0.86
31.09

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -7.46
CLVS's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CLVS: -7.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLVS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -9.06  Med: 0.00 Max: 0
Current: -7.46
-9.06
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 
comment on CLVS Mar 06 2013 

More From Other Websites
CLOVIS ONCOLOGY, INC. Financials Aug 20 2015
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Aug 12 2015
Clovis Oncology Strikes Deal with Roche for Rociletinib Aug 12 2015
Genentech cranks up partnerships for new generation of cancer drugs Aug 12 2015
Clovis Oncology Enters into Clinical Trial Collaboration Aug 11 2015
CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2015
Clovis Oncology Could Pass $100 By Year-End: Here's Why Aug 07 2015
Edited Transcript of CLVS earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
Clovis reports 2Q loss Aug 06 2015
Clovis reports 2Q loss Aug 06 2015
Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today Aug 06 2015
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2015
Clovis Oncology Announces Second Quarter 2015 Operating Results Aug 06 2015
5 Big FDA Decisions Expected in August Aug 06 2015
Q2 2015 Clovis Oncology Inc Earnings Release - After Market Close Aug 06 2015
Clovis Oncology Completes U.S. and E.U. Regulatory Submissions for Rociletinib for the Treatment of... Aug 03 2015
Clovis Oncology to Announce Second Quarter 2015 Financial Results and Host Webcast Conference Call... Jul 23 2015
Top Analyst Upgrades and Downgrades: Amazon, Clovis, Glaukos, Hertz, Peabody, Whiting and More Jul 20 2015
Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs Jul 20 2015
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jul 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK